Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Cotavance Drug-Eluting Balloon (DEB) Catheter

A paclitaxel-eluting balloon catheter for the minimally invasive treatment of peripheral artery obstruction in patients who require angioplasty of the femoropopliteal arteries. 

Dior Drug-Eluting Balloon (DEB) Catheter

A paclitaxel-eluting balloon catheter for treatment of coronary in-stent restenosis, bifurcated coronary artery lesions, and lesions in small-diameter coronary arteries.

Zaltrap (ziv-aflibercept)

An intravenous antivascular endothelial growth factor agent for second-line treatment of metastatic colorectal cancer.

Stivarga for Gastrointestinal Stromal Tumors

An oral multikinase inhibitor for the third-line treatment of metastatic and/or unresectable gastrointestinal stromal tumors in patients whose disease has progressed despite prior treatment.